193 related articles for article (PubMed ID: 36521246)
1. Molecular targets that sensitize cancer to radiation killing: From the bench to the bedside.
Sriramulu S; Thoidingjam S; Brown SL; Siddiqui F; Movsas B; Nyati S
Biomed Pharmacother; 2023 Feb; 158():114126. PubMed ID: 36521246
[TBL] [Abstract][Full Text] [Related]
2. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer.
Huang RX; Zhou PK
Signal Transduct Target Ther; 2020 May; 5(1):60. PubMed ID: 32355263
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer.
Yang SH; Kuo TC; Wu H; Guo JC; Hsu C; Hsu CH; Tien YW; Yeh KH; Cheng AL; Kuo SH
World J Gastroenterol; 2016 Aug; 22(32):7275-88. PubMed ID: 27621574
[TBL] [Abstract][Full Text] [Related]
4. Poly (ADP-ribose) polymerase inhibitors sensitize cancer cells to hypofractionated radiotherapy through altered selection of DNA double-strand break repair pathways.
Seo Y; Tamari K; Takahashi Y; Minami K; Tatekawa S; Isohashi F; Suzuki O; Akino Y; Ogawa K
Int J Radiat Biol; 2022; 98(7):1222-1234. PubMed ID: 34919022
[TBL] [Abstract][Full Text] [Related]
5. Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways.
Morgan MA; Lawrence TS
Clin Cancer Res; 2015 Jul; 21(13):2898-904. PubMed ID: 26133775
[TBL] [Abstract][Full Text] [Related]
6. Ataxia-telangiectasia mutated and the Mre11-Rad50-NBS1 complex: promising targets for radiosensitization.
Kuroda S; Urata Y; Fujiwara T
Acta Med Okayama; 2012; 66(2):83-92. PubMed ID: 22525466
[TBL] [Abstract][Full Text] [Related]
7. ATM as a target for novel radiosensitizers.
Sarkaria JN; Eshleman JS
Semin Radiat Oncol; 2001 Oct; 11(4):316-27. PubMed ID: 11677656
[TBL] [Abstract][Full Text] [Related]
8. DNA topoisomerase I-targeting drugs as radiation sensitizers.
Chen AY; Choy H; Rothenberg ML
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):39-46. PubMed ID: 10550825
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.
Chalmers AJ; Lakshman M; Chan N; Bristow RG
Semin Radiat Oncol; 2010 Oct; 20(4):274-81. PubMed ID: 20832020
[TBL] [Abstract][Full Text] [Related]
10. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints.
Molkentine JM; Molkentine DP; Bridges KA; Xie T; Yang L; Sheth A; Heffernan TP; Clump DA; Faust AZ; Ferris RL; Myers JN; Frederick MJ; Mason KA; Meyn RE; Pickering CR; Skinner HD
Int J Radiat Biol; 2021; 97(8):1121-1128. PubMed ID: 32073931
[TBL] [Abstract][Full Text] [Related]
11. Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization.
Maier P; Hartmann L; Wenz F; Herskind C
Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26784176
[TBL] [Abstract][Full Text] [Related]
12. Selective Inhibition of Parallel DNA Damage Response Pathways Optimizes Radiosensitization of Glioblastoma Stem-like Cells.
Ahmed SU; Carruthers R; Gilmour L; Yildirim S; Watts C; Chalmers AJ
Cancer Res; 2015 Oct; 75(20):4416-28. PubMed ID: 26282173
[TBL] [Abstract][Full Text] [Related]
13. Radiation-induced synthetic lethality: combination of poly(ADP-ribose) polymerase and RAD51 inhibitors to sensitize cells to proton irradiation.
Wéra AC; Lobbens A; Stoyanov M; Lucas S; Michiels C
Cell Cycle; 2019 Aug; 18(15):1770-1783. PubMed ID: 31238782
[TBL] [Abstract][Full Text] [Related]
14. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.
Löser DA; Shibata A; Shibata AK; Woodbine LJ; Jeggo PA; Chalmers AJ
Mol Cancer Ther; 2010 Jun; 9(6):1775-87. PubMed ID: 20530711
[TBL] [Abstract][Full Text] [Related]
15. Targeting base excision repair as a sensitization strategy in radiotherapy.
Vens C; Begg AC
Semin Radiat Oncol; 2010 Oct; 20(4):241-9. PubMed ID: 20832016
[TBL] [Abstract][Full Text] [Related]
16. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
Li S; Wang L; Wang Y; Zhang C; Hong Z; Han Z
J Hematol Oncol; 2022 Oct; 15(1):147. PubMed ID: 36253861
[TBL] [Abstract][Full Text] [Related]
17. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.
Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN
Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061
[TBL] [Abstract][Full Text] [Related]
18. Radioprotection and cell cycle arrest of intestinal epithelial cells by darinaparsin, a tumor radiosensitizer.
Tian J; Doi H; Saar M; Santos J; Li X; Peehl DM; Knox SJ
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1179-85. PubMed ID: 24210080
[TBL] [Abstract][Full Text] [Related]
19. Harnessing the targeting potential of differential radiobiological effects of photon versus particle radiation for cancer treatment.
Zhang J; Si J; Gan L; Zhou R; Guo M; Zhang H
J Cell Physiol; 2021 Mar; 236(3):1695-1711. PubMed ID: 32691425
[TBL] [Abstract][Full Text] [Related]
20. Application of Radiosensitizers in Cancer Radiotherapy.
Gong L; Zhang Y; Liu C; Zhang M; Han S
Int J Nanomedicine; 2021; 16():1083-1102. PubMed ID: 33603370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
